Docking of CRISPR-identified candidate targets with kinase inhibitor libraries.
Thu, 24 Apr
|On Going Project
This study aims to explore the therapeutic potential of kinase inhibitors against novel targets identified through CRISPR-based functional genomic screening.
Time & Location
24 Apr 2025, 7:00 pm – 11:00 pm
On Going Project
About the event
Background:
CRISPR-Cas9-based genome editing has revolutionized the way researchers identify essential genes and potential therapeutic targets, especially in oncology, neurodegeneration, and infectious diseases. Large-scale CRISPR screens can pinpoint genes critical to cell survival or disease progression. Among these, kinases often emerge as key players due to their role in cell signaling, growth, and apoptosis.
Kinase inhibitors are a well-established class of therapeutic agents, with multiple FDA-approved drugs already targeting aberrant kinase activity in cancer and other diseases. However, many candidate targets revealed by CRISPR remain unexplored in terms of druggability.
Aim of the Study:
The study intends to dock a selected panel of CRISPR-identified candidate proteins with libraries of known and novel kinase inhibitors to predict binding affinities and interaction modes, thus evaluating the therapeutic potential of these novel targets.